Support on Ebola
Gates Package, pp.77-78 · gates:email:00046
Page text: p.77, p.78 · original PDF
- Date
- 2014-08-07 19:17
- Type
- email · email
This text appears inside a quoted reply chain — it is evidence that the message was circulating, not necessarily a new message.
gatesfoundation.org]
Dear Francis and Tony,
It is clear that the problem, concern and media attention surrounding the treatment of the two individuals now in
Atlanta add further weight to the Ebola outbreak concerns, which we have discussed by email over the past week or so.
Although the overall burden of disease due to Ebola is not of the magnitude of the conditions we address strategically,
we recognize that the current situation calls for action and places considerable pressure on your agency and WHO and
others of our key partners. For these reasons we have provided emergency funds to WHO and UNICEF to support public
health measures as well as on the ground human resources in the target countries as one in kind contribution to the
problem.
We would also like to be supportive of your efforts, if doing so can add value. One challenge is that we believe that
interventions that could help to interdict the current epidemic are needed the most. Interventions that are not ready to
give to patients in the relatively near term will not be of help for this emergent situation.
We understand that there are efforts with GSK and the VRC to scale up the lot of the ChAd3 vaccine, which is due to go
into FIH studies this fall and for which additional doses might be available for evaluation in at risk individuals by early
2015; we believe that Wellcome may be interested in supporting this effort.
We also understand that there are very limited supplies of ZMapp (~12 courses of therapy). Assuming an appropriate
approach can be designed with input from relevant stakeholders (i.e., one which provides for equity in opportunity for
participation in an interventional trial that extends beyond foreign health workers to include indigenous individuals), we
would be willing to assist with partial funding to generate more product in partnership with NIH and other relevant
agencies. We can also provide in-kind CMC expertise through two MAb manufacturing experts with considerable
industry experience on our team. Please let us know if this would be useful to you.
We appreciate your frontline efforts to address this problem and look forward to helping where we might.
Warm regards,
Trevor
<image001.png>
Trevor Mundel, MD, PhD
President, Global Health Program
v
F
E
gatesfoundation.org
Amissa Cormier
Senior
Progr
tant
Global Health Office
of
the
President
v
M
E
gatesfoundation.org
Bill & Melinda Gates Foundation
www.gatesfoundation.org
2.
Links shared
- other www.gatesfoundation.org